Multi-dimensional visualization for the morphology of lubricant stearic acid particles and their distribution in tablets

The shapes of particles and their distribution in tablets, controlled by pretreatment and tableting process, determine the pharmaceutical performance of excipient like lubricant. This study aims to provide deeper insights to the relationship of the morphology and spatial distribution of stearic acid(SA) with the lubrication efficiency, as well as the resulting tablet property. Unmodified SA particles as flat sheet-like particles were firstly reprocessed by emulsification in hot water to obtain the reprocessed SA particles with spherical morphology. The three-dimensional(3 D) information of SA particles in tablets was detected by a quantitative and non-invasive 3 D structure elucidation technique, namely, synchrotron radiation X-ray micro-computed tomography(SR-μCT). SA particles in glipizide tablets prepared by using unmodified SA(GUT), reprocessed SA(GRT), as well as reference listed drug(RLD) of glipizide tablets were analyzed by SR-μCT. The results showed that the reprocessed SA with better flowability contributed to similarity of breaking forces between that of GRT and RLD. SA particles in GRT were very similar to those in RLD with uniform morphology and particle size, while SA particles in GUT were not evenly distributed. These findings not only demonstrated the feasibility of SR-μCT as a new method in revealing the morphology and spatial distribution of excipient in drug delivery system, but also deepened insights of solid dosage form design into a new scale by powder engineering.

Effects of tripterygium glycosides combined with compoundα-keto acid tablets on inflammatory response, oxidative stress and urinary TGF-β1, IV-C levels in patients with chronic renal failure

Objective:To investigate the effects of tripterygium glycosides combined with compoundα-ketoacid tablets on inflammatory response, oxidative stress and urinary TGF-β1 and IV-C levels in patients with chronic renal failure.Methods: 102 patients with chronic renal failure admitted to Shuguang hospital from January 2017 to June 2018 were randomly divided into observation group (51 cases) and control group (51 cases). In the control group, the tripterygium glycosides tablets were orally administered, and the observation group was orally administered with tripterygium glycosides tablets and compoundα-keto acid tablets. The inflammatory response, oxidative stress index and urinary TGF-β1, IV-C levels were compared between the two groups.Results: There was no significant difference in CRP and TNF-α levels between the two groups before treatment (P>0.05). After treatment, the levels of CRP and TNF-α in the observation group were (9.32±1.10) mg/L and (3.14±0.36) ng/L, respectively, and the levels of CRP and TNF-α in the control group were (15.34±1.31) mg/ L, (5.01±0.53) ng / L. The CRP and TNF-α levels in the two groups were lower than those before treatment, and the CRP and TNF-α in the observation group were significantly lower than those in the control group (P<0.05). Before treatment, there was no significant difference in MDA, SOD and GSH-PX levels between the two groups (P>0.05). After treatment, the MDA level of the observation group was (3.01±0.32) μmol/L, and the MDA level of the control group was (5.17±0.61) μmol/L. The MDA of the two groups was lower than that before treatment, and the MDA of the observation group was significantly lower than that of the control group (P<0.05). After treatment, the levels of SOD and GSH-PX in the observation group were (101.45±13.16) U/L and (94.83±7.17) U/L, respectively. The levels of SOD and GSH-PX in the control group were (88.87±12.05) U/L, (87.38 ± 6.32) U/L. The SOD and GSH-PX of the two groups were higher than those before treatment, and the SOD and GSH-PX of the observation group were significantly higher than the control group (P<0.05). Before treatment, there was no significant difference in TGF-β1 and IV-C levels between the two groups (P>0.05). After treatment, the levels of TGF-β1 and IV-C in the observation group were (1.05±0.24) ng/L and (5.05±1.13) μg/L, respectively, and the levels of TGF-β1 and IV-C in the control group were (1.36±, respectively). 0.26) ng/L, (7.07±1.24) μg/L. The levels of TGF-β1 and IV-C in the two groups were lower than those before treatment, and the TGF-β1 and IV-C in the observation group were significantly lower than those in the control group (P<0.05).Conclusion: Tripterygium glycosides combined with compound -keto acid tablets can effectively reduce the inflammatory response, oxidative stress and renal interstitial fibrosis in patients with chronic renal failure.

Preparation and Characterization of Orally Fast-Disintegrating Mini-Tablets Containing Diphenhydramine Hydrochloride and Aspartic or Glutamic Acid as an Umami Amino Acid

The aim of this study was to prepare diphenhydramine hydrochloride (DPH)-loaded orally fast-disintegrating mini-tablets (OFDMTs) containing either L-aspartic acid (Asp) or L-glutamic acid (Glu) as bitterness-suppressant, to characterize the prepared tablets and to evaluate their bitterness under conditions mimicking those of the oral cavity. The preparation of five formulation batches of the OFDMTs involved mixing DPH, with or without two different concentrations of Asp or Glu, and a premix containing a disintegrating agent. When all ingredients were well mixed, the mixture was directly compacted to form small (4 mm diameter) DPH-loaded OFDMTs. There were only small differences between the tablets with respect to mass, diameter, width and hardness. The disintegration times of the five formulation batches of DPH-loaded OFDMTs were measured using the OD-mate, a disintegration test apparatus in which conditions resemble those of the oral cavity. The disintegration times were all within 10 s of exposure to a medium representing the inside of the oral cavity. Rapid release profiles were observed for DPH, Asp and Glu in these dissolution tests. The taste sensor outputs of samples taken at different times (5 - 30 s) from the dissolution test solutions of the four DPH-loaded OFDMTs containing Asp or Glu were significantly inhibited compared with those of control DPH-loaded OFDMT. These results suggest that the inclusion of Asp or Glu in DPH-loaded OFDMTs is sufficient to mask bitterness in the oral cavity for the first 30 s after the tablet is placed in the mouth. It is anticipated that swallowing will have taken place within 30 s.

Formulation Development of Generic Omeprazole 20 mg Enteric Coated Tablets

Omeprazole is a potent proton pump inhibitor with powerful inhibition of secretion of gastric juice. Oral site-specific drug delivery systems have recently attracted a great interest for the local treatment of bowel disease and for improving systemic absorption of drugs which are unstable in the stomach. However, microenvironment in the gastrointestinal tract and varying absorption mechanisms cause hindrance for the formulation and optimization of oral drug delivery. The objective of the study was to develop and optimize enteric coating process for omeprazole tablets. Different batches of core tablets were sub coated, one set sub coated with opadry and another with a mixture of light magnesium oxide, magnesium stearate and absolute alcohol omeprazole magnesium. Seal coating was applied by using opadry to achieve certain weight gain and to protect omeprazole from acidic coating polymers. A comparative dissolution test was performed. The variation of thickness and diameter were observed to be minimal with a weight gain of 3% - 4% of enteric polymer. Disintegration test showed that in each tested batch the enteric coated layer remained intact in 0.1N HCl for 2 hours and when exposed to alkaline media of phosphate buffer pH 6.8, it dissolved within few minutes. Dissolution release was 98.8% to 102.4% within two hours when the product was exposed to phosphate buffer pH 6.8 after 2 hours. The similarity and dis-similarity factors were calculated and observed to be 54 to 61 and 4 to 5 respectively. Therefore a simple and good enteric coating process was developed and tested with potential for transfer this technology into local pharmaceutical industries using cheap and easily available materials.

Determination of Two Synthetic Pigments in Lifei Tablets by HPLC and LC-MS/MS Spectrometry

[Objectives]To identify stained Schisandrae Chinensis Fructus in Lifei Tablets with carmine and acid red 73 as target substances.[Methods]High performance liquid chromatography(HPLC)and liquid chromatography tandem-mass spectrometry(LC-MS/MS)was used to analyze the 70%methanol extract of the drug.The HPLC was equipped with an Inertstain-C_(18)(250 mm×4.6 mm,5μm)chromatographic column.The mobile phase was acetonitrile-5 mmol/L ammonium acetate solution,gradient elution:volume flow rate of 1.0 mL/min,column temperature of 30℃,detection wavelength of 509 nm.LC-MS/MS was equipped with a Waters-C_(18)(2.1 mm×150 mm,1.7μm)chromatographic column,the mobile phase was methanol-0.1%formic acid solution(containing 5 mmol/L ammonium acetate),gradient elution;the volume flow rate was 0.3 mL/min;ESI ion source,positive ion mode,full scan of primary and secondary mass spectrometry.[Results]Carmine and acid red 73 showed good linear relationship in HPLC and LC-MS/MS,with r greater than 0.995.The sample recovery and RSD values of HPLC and LC-MS/MS met the requirements.The RSD of the results determined by HPLC and LC-MS/MS was not greater than 5.0%.Both methods had good compatibility and could be used for the examination of carmine and acid red 73 in Lifei Tablets.[Conclusions]The method is reliable and reproducible and can be used to identify stained Schisandrae Chinensis Fructus in Lifei Tablets.

高效液相色谱法测定α-硫辛酸绿茶片中α-硫辛酸的含量

目的 建立α-硫辛酸绿茶片中α-硫辛酸的含量测定方法。方法 利用高效液相色谱(HPLC)技术,采用Alltima C_(18)柱(250 mm×4.6 mm,5μm),流动相为乙腈-0.1%磷酸溶液(55∶45),流速为1.0 mL·min^(-1),检测波长为215 nm,柱温为30℃。结果 α-硫辛酸在102.6~307.7μg·mL^(-1)与峰面积呈良好的线性关系,相关系数(r)为1.000;精密度、重复性和稳定性考察RSD均小于2.0%;3个浓度的加样回收率为98.44%~100.2%,RSD值均小于1.0%。结论 该方法准确、简单、快速,能够用于α-硫辛酸绿茶片中α-硫辛酸的含量测定。

玛咖灵芝片缓解小鼠体力疲劳的研究

研究玛咖灵芝片对改善小鼠体力劳动过度的疲倦状态,增加体力和身体机能的作用.本次实验采用清洁级雄性ICR小鼠作为动物模型,以体重为划分依据随机分组,包括低、中、高剂量组和阴性对照组4组.其中低、中、高剂量组分别给予剂量为0.38、0.75、2.25 g/kg·bw的玛咖灵芝片药剂进行灌胃;阴性对照组为20 mL/kg·bw的蒸馏水灌胃.每天给药1次,共给药30 d.实验期间,小鼠每日进行负重游泳实验,与此同时,使用比色法对血清中尿素、肝糖原和血乳酸的含量进行检测.比色法检测结果显示,与阴性对照组相比较,玛咖灵芝片不同剂量组的小鼠负重游泳的时间明显延长(P<0.05).另外,玛咖灵芝片不同剂量组的小鼠负重游泳后,其血浆尿素浓度均明显低于阴性对照组(P<0.05),肝脏糖原含量均显著高于阴性对照组(P<0.05),血乳酸浓度均显著低于阴性对照组(P<0.05).玛咖灵芝片可通过提高肝糖原含量和阻止血乳酸堆积的方式有效改善小鼠体力劳动过度的疲倦状态,增加体力和身体机能.

珍黄安宫片联合抗癫痫药物治疗痰火扰神型癫痫的效果

目的:探究珍黄安宫片联合抗癫痫药物治疗痰火扰神型癫痫的效果。方法:选取2020年3月—2023年3月大连市第三人民医院收治的痰火扰神型癫痫患者106例为研究对象,以随机数字表法分为对照组(n=53,抗癫痫药物治疗)和观察组(n=53,珍黄安宫片联合抗癫痫药物治疗)。比较两组临床疗效、氧化应激指标情况,统计患者癫痫发作情况及药物不良反应发生率。结果:观察组临床疗效总有效率高于对照组,差异有统计学意义(P=0.038);治疗后,两组一氧化氮(NO)、超氧化物歧化酶(SOD)水平高于治疗前,丙二醛(MDA)水平低于治疗前,且观察组NO、SOD水平高于对照组,MDA水平低于对照组,差异有统计学意义(P<0.05);治疗后,两组癫痫发作频率及癫痫发作持续时间均较治疗前下降,且观察组低于对照组,差异有统计学意义(P<0.05);两组药物不良反应发生率比较,差异无统计学意义(P>0.05)。结论:珍黄安宫片联合抗癫痫药物治疗痰火扰神型癫痫疗效显著,能够改善患者氧化应激水平,减少癫痫发作,缩短癫痫发作时间,安全性较高。

马来酸依那普利叶酸片治疗H型高血压的效果及对脑卒中的预防作用

目的:分析马来酸依那普利叶酸片治疗H型高血压的效果及对脑卒中的预防作用。方法:选取2013年4月—2020年6月梧州市红十字会医院心内科治疗的H型高血压患者201例为研究对象,随机分为观察组(101例)和对照组(100例)。对照组口服厄贝沙坦片治疗,观察组口服马来酸依那普利叶酸片治疗。比较两组血压、血清同型半胱氨酸(Hcy)、不良反应发生情况、脑卒中发生率。结果:治疗前后,两组收缩压(SBP)、舒张压(DBP)水平比较,差异无统计学意义(P>0.05);治疗后,两组SBP、DBP水平低于治疗前,差异有统计学意义(P<0.05)。治疗前,两组Hcy水平比较,差异无统计学意义(P>0.05);治疗后,两组Hcy水平低于治疗前,观察组低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05);观察组脑卒中发生率低于对照组,差异有统计学意义(P=0.049)。结论:马来酸依那普利叶酸片治疗H型高血压患者可有效降低血压、Hcy水平及脑卒中发生率。

硫辛酸胶囊联合甲钴胺片治疗糖尿病周围神经病变的临床疗效

目的 分析硫辛酸胶囊的基础上辅助甲钴胺片治疗糖尿病周围神经病变(DPN)患者的临床效果。方法 本文的研究对象为80例糖尿病周围神经病变患者,根据随机数字法主要分为观察组与对照组。对照组40例患者均以甲钴胺片进行治疗,观察组40例患者均以硫辛酸胶囊联合甲钴胺片治疗。对比两组的临床疗效、运动神经传导速度(MNCV)、感觉神经传导速度(SNCV)、多伦多临床评分系统(TCSS)评分。结果 对比于对照组,观察组患者的总有效率明显较高(P<0.05)。治疗后,与对照组对比,观察组患者MNCV与SNCV升高(P<0.05)。治疗后与对照组对比,观察组患者的TCSS评分较低(P<0.05)。结论 以硫辛酸胶囊辅助甲钴胺片治疗DPN患者可改善运动神经传导速度、感觉神经传导速度,延缓疾病进展,提升治疗效果,值得临床借鉴、推广。

扶正化瘀片联合多烯磷脂酰胆碱治疗慢性乙肝肝硬化患者的疗效

目的:探讨扶正化瘀片联合多烯磷脂酰胆碱治疗慢性乙肝肝硬化患者的疗效及其对肝功能、肝纤维化和血清指标的影响。方法:选取106例慢性乙肝肝硬化患者,按照治疗方式不同分为对照组和研究组,每组各53例。对照组给予常规治疗和多烯磷脂酰胆碱治疗;研究组在对照组基础上给予扶正化瘀片治疗,两组均治疗24周。比较两组患者的疗效、肝功能、肝纤维化指标、血清指标水平及不良反应发生情况。结果:研究组的临床总有效率为96.23%,高于对照组的83.02%(P<0.05)。治疗后,两组患者的总胆红素(TBIL)、丙氨酸氨基转移酶(ALT)、门冬氨酸氨基转移酶(AST)、透明质酸酶(HA)、Ⅲ型前胶原(PCⅢ)、Ⅳ型胶原(IV-C)、层粘连蛋白(LN)、D二聚体(D-D)、总胆汁酸(TBA)水平均降低(P<0.05),且研究组均低于对照组(P<0.05);两组患者的白蛋白(ALB)、胆碱酯酶(CHE)水平均升高(P<0.05),且研究组高于对照组(P<0.05),两组不良反应总发生率无统计学差异(P>0.05)。结论:扶正化瘀片联合多烯磷脂酰胆碱治疗慢性乙肝肝硬化患者疗效显著,可有效改善患者肝功能,减轻肝纤维化,调节D-D、TBA及CHE的表达水平,并具有较好的安全性。

经典藏药如意珍宝片多次给药的药代动力学研究

目的:探讨经典藏药如意珍宝片多次给药的血浆药代动力学特征,为临床用药提供参考和依据。方法:选取斯泼累格·多雷(SD)大鼠12只,雌雄各半,分为对照组和给药组,连续给药7 d,在最后一次给药前0 h及给药开始后0.25、0.5、0.75、1、2、4、8、24、48 h眼眶采血,测定血浆中沉香四醇、异甘草素、胡椒碱、阿魏酸的药代参数。结果:血浆中沉香四醇、异甘草素、胡椒碱、阿魏酸的药代参数达峰时间大部分分别在1~8、0.25、0.25~8、0.25 h;C_(max)分别为(140±53.90)、(8.31±6.34)、(33.4±22.20)、(15.7±7.90)ng/mL;t_(1/2)分别为(10.1±3.85)、(8.51±4.23)、(4.45±1.35)、(67.3±55.10);AUC_(0-t)分别为(1 890±1 440)、(45.6±14.3)、(288±150)、(443±165) h×ng/mL;MRT_(0-∞)分别为(13.2±7.45)、(9.80±4.27)、(4.91±1.34)、(103±77.10) h。沉香四醇、异甘草素、胡椒碱在大鼠体内主要药动学参数差异无统计学意义(P>0.05),阿魏酸在大鼠体内主要药动学参数(C_(max)、AUC_(0-t))差异有统计学意义(P<0.05)。结论:本研究建立了适用于如意珍宝片多次给药后的沉香四醇、异甘草素、胡椒碱、阿魏酸4种成分的药代动力学的研究方法,分析其药代动力学特征,指导临床给药周期和间隔。

UPLC-MS/MS检测伤痛宁片中5个马兜铃酸成分

目的:测定伤痛宁片中马兜铃酸类成分的含量。方法:采用超高效液相色谱-质谱法测定伤痛宁片中马兜铃酸Ⅰ、马兜铃酸Ⅱ、马兜铃酸Ⅲa、马兜铃酸AA-Ⅳa、马兜铃内酰胺Ⅰ的含量。采用Agilentporoshell C18(100 mm×2.1 mm,2.7μm)色谱柱,以乙腈(A)-0.1%甲酸水溶液(B)为流动相梯度洗脱;电喷雾正离子模式,多反应监测,进样量为1μL,以基质标准曲线外标法计算伤痛宁片中5个马兜铃酸成分含量。结果:18批样品中检出马兜铃酸Ⅰ质量分数为0.01~0.05 mg·kg^(–1),马兜铃酸Ⅱ和马兜铃酸Ⅲa未检出,马兜铃酸AA-Ⅳa质量分数为0.26~1.00 mg·kg^(–1),马兜铃内酰胺Ⅰ质量分数为0.40~2.17 mg·kg^(–1)。结论:建立的含量测定方法,可为伤痛宁片及含马兜铃酸中药制剂的临床应用和安全监管提供参考。

益母草当归锭的制备及主成分阿魏酸含量测定

为确定益母草当归锭的制备工艺,并制定益母草当归锭主要成分阿魏酸的含量限度,本试验以益母草和当归为原料,将其超微粉碎后得到微粉,加入黏合剂,通过湿法制粒得到软材,再经过制粒、整粒、压片等步骤,制得益母草当归锭;采用高效液相色谱法对阿魏酸含量检测方法的专属性、线性、重复性、精密度、耐受性以及加样回收试验等方法学进行考察,并通过对制备的10批样品进行检测,建立益母草当归锭中阿魏酸的含量检测方法及限度。结果显示,制得的益母草当归锭为表面光滑的圆柱状,每锭质量达120 g;阿魏酸的高效液相色谱检测方法专属性、线性、重复性、精密度、耐受性以及加样回收试验结果均良好;测得10批样品中阿魏酸的含量为0.34~0.52 mg/g,考虑到当归药材的产地、来源、炮制加工、生产及贮存等因素对阿魏酸含量的影响,将阿魏酸含量限度在最小值的基础上下降10%,暂定阿魏酸含量不得少于0.31 mg/g,作为益母草当归锭的含量检测限度。结果表明,本试验益母草当归锭制备方法简单,每锭载药量大,1锭即可达到治疗剂量,方便投喂,建立的阿魏酸高效液相色谱含量检测方法稳定、可行,可用于益母草当归锭的质量控制。

非布司他联合塞来昔布治疗痛风性关节炎的效果分析

目的:分析非布司他联合塞来昔布治疗痛风性关节炎的效果。方法:选取2023年1—12月南通大学附属江阴市人民医院收治的痛风性关节炎患者80例作为研究对象,随机分为传统组和联合组,各40例。传统组给予塞来昔布治疗,联合组在传统组基础上给予非布司他治疗。对比两组治疗效果、血清尿酸水平、炎性因子水平、生活质量。结果:联合组治疗有效率高于传统组(P=0.023)。治疗前,两组血清尿酸水平对比,差异无统计学意义(P>0.05);治疗后,两组血清尿酸水平低于治疗前,且联合组低于传统组(P<0.001)。治疗前,两组炎性因子水平比较,差异无统计学意义(P>0.05);治疗后,两组髓过氧化物酶、肿瘤坏死因素-α、白细胞介素-1β、C反应蛋白水平低于治疗前,且联合组低于传统组(P<0.05)。治疗前,两组生活质量评分比较,差异无统计学意义(P>0.05);治疗后,两组疼痛程度、活动能力、睡眠质量、满意度评分高于治疗前,且联合组高于传统组(P<0.05)。结论:非布司他联合塞来昔布治疗痛风性关节炎的效果显著,可降低患者血清尿酸水平,减轻炎性反应,改善其生活质量。

糖宁孜亚比土斯片基于高糖人结直肠腺癌细胞模型对小克里斯滕森菌-TαMCA-FXR/TGR5轴的调控作用

目的探讨糖宁孜亚比土斯片(TZT)基于高糖人结直肠腺癌细胞模型对小克里斯滕森菌科-牛磺-α鼠胆酸钠盐(TαMCA)-法尼醇X受体(FXR)/G蛋白偶联受体5轴的调控作用。方法配制菌株液体培养基、高糖培养基、TZT溶液、TαMCA溶液,培养菌株,制备灭活小克里斯滕森菌及其发酵液,常规培养人结直肠腺癌细胞(Caco-2细胞)。取部分细胞随机分为对照组、灭活菌体组、106 CFU/mL活菌组、10^(7)CFU/mL活菌组、10^(8)CFU/mL活菌组、10^(9)CFU/mL活菌组,对照组用无菌Caco-2专用培养基培养,灭活菌体组用灭活小克里斯滕森菌菌体悬液干预,106 CFU/mL活菌组、10^(7)CFU/mL活菌组、10^(8)CFU/mL活菌组、10^(9)CFU/mL活菌组分别在含有完全分化的Caco-2细胞培养板孔中加入2 mL 10^(9)CFU、10^(8)CFU、10^(7)CFU、10^(6)CFU的小克里斯滕森菌活菌干预。取部分细胞随机分为对照组、发酵培养液组,对照组用无菌Caco-2专用培养基培养,发酵培养液组用小克里斯滕森菌发酵液干预。取部分细胞随机分为对照组、高糖组及TZT低、中、中高、高剂量组,除对照组外其他各组加入8 g/L高糖培养基干预24 h,TZT低、中、中高、高剂量组分别加入10、25、50、100μg/mL的TZT含药培养基干预24 h。取部分细胞随机分为对照组、25μmol/L TαMCA组、50μmol/L TαMCA组,后两组换入25、50μmol/L的含TαMCA培养基干预24 h。实时荧光定量PCR法检测FXR、TGR5、IL-8、IL-10 mRNA,Western blotting法检测FXR、TGR5蛋白。结果与对照组比较,10^(6)CFU/mL活菌组、10^(7)CFU/mL活菌组、10^(8)CFU/mL活菌组、10^(9)CFU/mL活菌组TGR5 mRNA表达高(P均<0.05),FXR、IL-8、IL-10 mRNA表达差异无统计学意义(P均>0.05)。与对照组比较,菌发酵液组FXR mRNA表达高(P均<0.05),TGR5 mRNA表达差异无统计学意义(P均>0.05)。与对照组比较,高糖组FXR mRNA表达高(P<0.05),TGR5 mRNA表达低(P<0.05),FXR、TGR5蛋白表达差异无统计学意义(P均>0.05)。与高糖组比较,各TZT组FXR mRNA表达低(P均<0.05),TGR5 mRNA表达高(P均<0.05),FXR、TGR5蛋白表达差异无统计学意义(P均>0.05)。与对照组比较,25μmol/L TαMCA组FXR mRNA、蛋白表达低(P均<0.05),TGR5 mRNA、蛋白表达高(P均<0.05);50μmol/L TαMCA组FXR蛋白表达低(P<0.05)。结论小克里斯滕森菌具有一定的抗炎效果,TZT可能通过促进小克里斯滕森菌的生长,产生代谢产物影响胆汁酸代谢,促进TαMCA肠道内累积,进一步抑制肠FXR表达,促进TGR5表达。

胰激肽原酶肠溶片治疗糖尿病周围神经病变患者的效果

目的:观察胰激肽原酶肠溶片治疗糖尿病周围神经病变(DPN)患者的效果。方法:选取2021年1月至2023年1月该院收治的94例DPN患者进行前瞻性研究,按随机数字表法将其分为对照组和观察组各47例。对照组采用硫辛酸联合甲钴胺治疗,观察组在对照组基础上给予胰激肽原酶肠溶片治疗,比较两组临床疗效、治疗前后氧化应激指标[超氧化物歧化酶(SOD)、丙二醛(MDA)、总抗氧化能力(T-AOC)]水平和周围神经传导速度[运动神经传导速度(MNCV)、感觉神经传导速度(SNCV)]。结果:观察组治疗总有效率为97.87%(46/47),高于对照组的82.98%(39/47),差异有统计学意义(P<0.05);治疗后,观察组MDA水平低于对照组,SOD、T-AOC水平均高于对照组,差异有统计学意义(P<0.05);治疗后,观察组正中神经、腓总神经的SNCV、MNCV均高于对照组,差异有统计学意义(P<0.05)。结论:在硫辛酸联合甲钴胺治疗基础上采用胰激肽原酶肠溶片治疗DPN患者可提高治疗总有效率和周围神经传导速度,改善氧化应激指标水平,效果优于单纯硫辛酸联合甲钴胺治疗。

当归补血泡腾片的制备及质量分析

优选当归补血泡腾片的处方工艺,并对其质量进行分析。通过Box-Behnken响应面法优化制剂处方。通过TLC法对样品中阿魏酸、藁本内酯进行薄层鉴别。通过HPLC-CAD法对黄芪甲苷进行含量测定,通过HPLC-DAD法对样品中阿魏酸、毛蕊异黄酮葡萄糖苷进行含量测定。在当归黄芪提取物用量15%、柠檬酸用量22%、碳酸氢钠用量19%、聚乙二醇6000用量5%、可溶性淀粉用量39%时,制剂的综合评分最佳,实测值与预测值偏差为1.43%。崩解时限、重量差异、硬度、pH等检查符合药典规定。在TLC检测中,阿魏酸、藁本内酯主斑点清晰。黄芪甲苷、阿魏酸、毛蕊异黄酮葡萄糖苷的含量分别为448.38、242.31、526.02μg/g。实验确立的当归补血泡腾片处方科学合理,质量分析方法方便可靠。

UPLC-Q-Exactive-Orbitrap-MS法同时测定牛黄上清片中18种胆汁酸的含量

目的 建立超高效液相色谱-四极杆-静电场轨道阱高分辨质谱(UPLC-Q-Exactive-Orbitrap-MS)法同时测定牛黄上清片中牛磺胆酸、7-酮-3α,12-α-羟基胆烷酸、甘氨猪去氧胆酸、12-脱氢胆酸、甘氨胆酸、3-酮-7α,12α-二羟基-5β-胆烷酸、牛磺鹅去氧胆酸、3α-羟基-7-氧代-5β-胆烷酸、猪胆酸、牛磺脱氧胆酸钠、猪去氧胆酸、胆酸、甘氨鹅脱氧胆酸、甘氨脱氧胆酸、牛磺石胆酸钠、鹅去氧胆酸、去氧胆酸、石胆酸的含量。方法 分析采用Thermo Fisher Scientfic Bremen HYPERSIL GOLD色谱柱(2.1 mm×100 mm, 1.9μm);流动相0.1%甲酸-甲醇,梯度洗脱;体积流量0.2 mL/min;柱温40℃;加热电喷雾离子源;负离子扫描;平行反应监测模式。再进行化学模式识别。结果 18种胆汁酸在各自范围内线性关系良好(r≥0.999 5),平均加样回收率96.73%~104.07%,RSD 2.10%~4.07%。不同厂家样品中各胆汁酸在种类和含量上存在一定差异。结论 该方法灵敏可靠,专属性好,可用于牛黄上清片的质量控制。

沙库巴曲缬沙坦钠片联合叶酸治疗对H型高血压患者血压、sdLDL-C水平及血浆Hcy的影响

目的 探讨沙库巴曲缬沙坦钠片联合叶酸治疗对H型高血压患者血压、sdLDL-C水平及血浆Hcy的影响。方法 选取2021年10月至2022年9月于淄博市第一医院进行治疗的176例H型高血压患者为受试者,按照随机双盲法将其分为2组。对照组受试者采用沙库巴曲缬沙坦钠片进行治疗;研究组受试者在对照组基础上给予叶酸进行治疗。观察两组受试者临床疗效、血压、血脂代谢指标、血清炎症指标情况。结果 研究组受试者临床疗效总有效率为92.05%远高于对照组,差异有统计学意义(χ^(2)=3.965,P<0.05)。研究组受试者治疗后收缩压,舒张压均低于对照组,差异有统计学意义(t=6.007、4.186,P<0.05);经治疗后,研究组受试者血脂代谢指标TC、TG、HDL-C、LDL-C和sdLDL-C水平均较对照组低,差异有统计学意义,(t=19.705、19.105、13.304、13.466、10.713,P<0.05);两组受试者经治疗后,研究组受试者血清炎症指标IL-6、TNF-α、hs-CRP、Hcy均优于对照组,差异有统计学意义(t=19.705、19.105、13.304、13.466、10.713,P<0.05)。结论 沙库巴曲缬沙坦钠片联合叶酸治疗H型高血压具有较好的临床效果,能有效降低H型高血压患者的血压,改善患者血脂情况,同时降低患者体内的血清炎症指标,具有较高的临床应用价值,值得推广。